Joint Results Sample Clauses

Joint Results. All data and results (the “Joint Results”) generated by or resulting from the Global Product Development Plan, whether generated by one or both Parties, shall be owned jointly by the Parties and deemed the Confidential Information of both Parties, and subject to the restrictions on use and disclosure set forth in Article 12, with each Party deemed to be the receiving Party of such Confidential Information for purposes of Article 12.
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
Joint Results. As requested in the Consortium Agreement signed between the ONTOCHAIN Beneficiaries, among which the Cascade Funding Partner, all Results generated by the Selected Third Party in the course of the Research with one or several ONTOCHAIN Beneficiaries shall be jointly owned. Due to the mentoring and advising processes from the ONTOCHAIN Beneficiaries towards the development of the proposal by the Cascade Funding Partner, a 20% of ownership of any research and development activity outcomes excluding intellectual property rights is assigned to the ONTOCHAIN beneficiaries after the end of the subproject. Where such Joint Result is covered by intellectual property rights, the joint owners shall execute a joint ownership agreement regarding the allocation and the terms and conditions of Exploitation of the Joint Results as soon as possible and before any industrial or commercial Exploitation. Unless otherwise agreed: o each of the joint owners shall be entitled to use their Jointly Owned Results for internal non-commercial research activities and educational purposes on a royalty- free basis, and without requiring the prior consent of the other joint owner(s), and o each of the joint owners shall be entitled to otherwise exploit the Jointly Owned Results, including by granting non-exclusive licenses to third parties (without any right to sub-license), if the other joint owners are given:
Sample 1See All (4)
Joint Results. As requested in the Consortium Agreement signed between the ESMERA Beneficiaries, among which the Cascade Funding Partner, if, in the course of carrying out the Robotics Application Oriented Research Experiment , a Result is generated by the Selected Third Parties with one or several ESMERA Beneficiaries, they shall own Results jointly if it is not possible to establish the respective contribution of each Party or separate them for the purpose of applying for, obtaining or maintaining their protection Where such joint Result is covered by intellectual property rights, the joint owners shall execute a joint ownership agreement regarding the allocation and the terms and conditions of Exploitation of the joint Results as soon as possible and before any industrial or commercial Exploitation. Unless otherwise agreed: - each of the joint owners shall be entitled to use their jointly owned Results for internal non-commercial research activities and educational purposes on a royalty-free basis, and without requiring the prior consent of the other joint owner(s), and - each of the joint owners shall be entitled to otherwise Exploit the jointly owned Results, including by granting non-exclusive licenses to third parties (without any right to sub-license), if the other joint owners are given:
Sample 1Sample 2
Joint Results. In the case of joint results where the university’s share of the invention is no more than 25 %, the industrial partner has the right to file the first application exclusively in its own name. If the university’s share of the invention is more than 25 %, the arrangement corresponds to the one for research results based on research commissions, i.e. the first application is filed as a joint application either by the industrial partner or alternatively by the university, in the names of the university and the industrial partner. On the whole, in the case of joint results, foreign applications are filed in accordance with the arrangements regarding research commissions (see 2.4.), i.e. by the industrial partner and exclusively in its own name. The remuneration for an invention which the industrial partner has to pay the university is settled as follows in the case of joint results: if the university’s share of the invention is less than 50 %, the remuneration for the invention is paid in the same way as with research commissions. If the university’s share of the invention is 50 %, the industrial partner pays the university remuneration for the invention as in the case of the university results, which will be discussed below (see 2.5.3), but deducting 10 % from the remuneration agreed for university results of that kind.
Sample 1Sample 2
Joint Results. 6.3.1 Title.................................................. 6.3.2 Use.................................................... 6.3.3
Sample 1
Joint Results. Where several Parties have jointly carried out work generating Results and where their respective share of the work cannot be ascertained, they shall have joint ownership of such Results. The joint owners must agree in writing on the allocation and terms of exercise of their joint ownership in a separate written agreement (i.e joint ownership agreement) to ensure compliance with their obligations under this Consortium Agreement. This agreement shall be drawn up as soon as necessary and in any event before any industrialand/or commercial exploitation of the Joint Results. The joint owners agree to endeavour the appointment among them of one joint owner in charge of the management and exploitation of the Joint Results in the name of all the other joint owners, notably for the granting of Access Rights to a requesting Party and for the negotiation of exploitation agreements with third parties. Unless otherwise agreed in the joint ownership agreement:
Sample 1
Joint Results. The costs associated with the application, retention, defence and enforcement of new rights in respect of joint results shall be borne by the industry partner unless it has assigned its substan- tive right to the university/research institute pursuant to Clause 8.2.1. After such an assignment of rights, the university/research institution shall bear the costs.
Sample 1
AutoNDA by SimpleDocs

Related to Joint Results

  • Joint Research Committee The Parties hereby establish a committee to facilitate the Research Program as follows:

  • Derogatory Material No material derogatory to an employee's conduct, service, character, or personality or any material which could have an adverse effect on an employee's status shall be placed in his personnel file unless the employee has had an opportunity to review the material. The employee shall acknowledge that he has had the opportunity to review such material by affixing his signature to the copy to be filed with the express understanding that such signature in no way indicated agreement with the contents thereof. The employee shall also have the right to submit a written answer to such material and his answer shall be reviewed by the Superintendent or his designee and attached to the file copy.

  • Joint Patents With respect to any potentially patentable Joint Invention, AstraZeneca shall have the first right, but not the obligation, to prepare patent applications based on such Joint Invention, to file and prosecute (including defense of any oppositions, interferences, reissue proceedings and reexaminations) such patent applications, and to maintain any Joint Patents issuing therefrom, in any jurisdictions throughout the Territory. FibroGen shall have the corresponding first right, but not the obligation, in any jurisdictions outside of the Territory other than China, in respect of which the China Agreement shall govern. If AstraZeneca determines in its sole discretion to abandon, cease prosecution or otherwise not file or maintain any Joint Patent anywhere in the Territory, then AstraZeneca shall provide FibroGen written notice of such determination at least thirty (30) days before any deadline for taking action to avoid abandonment (or other loss of rights) and shall provide FibroGen with the opportunity to prepare, file, prosecute and maintain such Joint Patent. The Party that is responsible for preparing, filing, prosecuting, and maintaining a particular Joint Patent (the “Prosecuting Party”) shall provide the other Party reasonable opportunity to review and comment on such prosecution efforts regarding such Joint Patent, and such other Party shall provide the Prosecuting Party reasonable assistance in such efforts. The Prosecuting Party shall provide the other Party with a copy of all material communications from any patent authority in the applicable jurisdictions regarding the Joint Patent being prosecuted by such Party, and shall provide drafts of any material filings or responses to be made to such patent authorities a reasonable amount of time in advance of submitting such filings or responses. In particular, each Party agrees to provide the other Party with all information necessary or desirable to enable the other Party to comply with the duty of candor/duty of disclosure requirements of any patent authority. Either Party may determine that it is no longer interested in supporting the continued prosecution or maintenance of a particular Joint Patent in a country or jurisdiction, in which case: (i) the disclaiming Party shall, if requested in writing by the other Party, assign its ownership interest in such Joint Patent in such country or jurisdiction to the other Party for no additional consideration; and (ii) if such assignment is effected, any such Joint Patent would thereafter be deemed a FibroGen Patent in the case of assignment to FibroGen, or a AstraZeneca Patent in the case of assignment to AstraZeneca; provided, however, that the disclaiming party would have an immunity from suit under such FibroGen Patent or AstraZeneca Patent, as the case may be, in the applicable country or jurisdiction. In addition, any Joint Patent that becomes a FibroGen Patent pursuant to the preceding sentence shall be excluded from the license granted to AstraZeneca in Section 7.1. Each Party shall bear its own internal costs in respect of the prosecution of Joint Patents. Out-of-pocket costs incurred in respect of the prosecution and maintenance of Joint Patents in the Territory shall be borne equally by AstraZeneca and FibroGen. In the event a Party elects to disclaim its interest in a Joint Patent, the costs incurred with respect to such Patent after the date of such disclaimer shall thereafter be borne exclusively by the other Party, without reimbursement or credit.

  • JOINT WORK PRODUCT This Agreement is the joint work product of H-GAC and the Contractor. This Agreement has been negotiated by H-GAC and the Contractor and their respective counsel and shall be fairly interpreted in accordance with its terms and, in the event of any ambiguities, no inferences shall be drawn against any party.

  • Third Party Information I understand, in addition, that the Company has received and in the future will receive from third parties confidential or proprietary information (“Third Party Information”) subject to a duty on the Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. During the term of my employment and thereafter, I will hold Third Party Information in the strictest confidence and will not disclose to anyone (other than Company personnel who need to know such information in connection with their work for the Company) or use, except in connection with my work for the Company, Third Party Information unless expressly authorized by an officer of the Company in writing.

  • Joint Inventions For Subject Inventions conceived or first actually reduced to practice under this Agreement that are joint Subject Inventions made by CONTRACTOR and USER, each Party shall have the option to elect and retain title to its undivided rights in such joint Subject Inventions.

  • Product Information Contractor shall provide the following information for all goods provided pursuant to this Agreement: manufacturer’s name, product code number, and pack size.

  • Joint Patent Rights 11.8.1 Genmab shall have the first right, but not the obligation, to file, prosecute, maintain and defend Patent Rights relating to Joint Inventions (“Joint Patent Rights”) throughout the Territory, at its sole expense, and Genmab shall give timely notice to CureVac, and, if during the Research Period, with a copy to the IP Sub-Committee, of any desire to not file patent applications claiming Joint Patent Rights or to cease prosecution and/or maintenance of Joint Patent Rights on a country-by-country basis and, in such cases, shall permit CureVac, in its sole discretion, to file such patent applications or to continue prosecution, maintenance or defense of such Joint Patent Rights at its own expense. At the latest [*****] before filing, the prosecuting Party shall give the non-prosecuting Party an opportunity to review and comment upon the text of any application with respect to such Joint Patent Right, shall consult with the non-prosecuting Party with respect thereto, shall not unreasonably refuse to address any of the non-prosecuting Party’s comments and supply the non-prosecuting Party with a copy of the application as filed, together with notice of its filing date and serial number. The prosecuting Party shall keep the non-prosecuting Party reasonably informed of the status of the actual and prospective prosecution, and maintenance, including but not limited to any substantive communications with the competent patent offices that may affect the scope of such filings, and the prosecuting Party shall give the non-prosecuting Party a timely, prior opportunity to review and comment upon any such substantive communication and shall consult with such non- prosecuting Party with respect thereto, and shall not unreasonably refuse to address any of such non-prosecuting Party’s comments.

  • Regulatory Information (a) All the notaries at De Pinna LLP are regulated through the Faculty Office of the Archbishop of Canterbury. Its address is The Faculty Office, 0 Xxx Xxxxxxxxx, Xxxxxxxxxxx, Xxxxxx XX0X 0XX, its telephone: 000 0000 0000, and it can be reached by email at xxxxxxx.xxxxxx@0xxxxxxxxxxxx.xxx. It also has a website at xxx.xxxxxxxxxxxxx.xxx.xx.

  • Development Records Each Party shall maintain complete, current and accurate records of all Development activities conducted by it hereunder, and all data and other information resulting from such activities. Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner appropriate for regulatory and patent purposes. Each Party shall document all non-clinical studies and Clinical Trials in formal written study reports according to Applicable Laws and national and international guidelines (e.g., ICH, cGCP, cGLP, and cGMP).

Time is Money Join Law Insider Premium to draft better contracts faster.